Status:
ACTIVE_NOT_RECRUITING
An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Pancreas Cancer
Gastrointestinal Adenocarcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to see if ultrasound images that are analyzed by a special computer program can be used to measure the size of PDAC tumors in the liver as accurately as CT scans that invo...
Eligibility Criteria
Inclusion
- Male and female patients, 18 years of age or older
- Confirmed diagnosis of PDAC or GI tract adenocarcinoma metastatic to liver
- Scheduled for imaging with contrast enhanced CT
Exclusion
- Inability to tolerate intravenous contrast medium
- All liver metastases ≤ 10 mm in maximal diameter on the contrast enhanced CT used for comparison to the planned research ultrasound
- Multiple confluent liver metastases or tumor burden \> 50% of the liver as estimated by a radiologist
Key Trial Info
Start Date :
April 6 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 6 2026
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT04837833
Start Date
April 6 2021
End Date
April 6 2026
Last Update
April 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065